Skip to main content

NINE MASTS CAPITAL Ltd

Source: SEC Form 13F · as of Mar 2026

NINE MASTS CAPITAL Ltd holds 42 biotech & pharma companies tracked by BioSniper, totaling $9.0M in value as of Mar 2026 (SEC Form 13F).

Companies held

42

Total value held

$9.0M

BioSniper AIPage evidence connected

Prepared research question

What matters most for Apellis Pharmaceuticals, Inc. (APLS)—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

CompanySharesValue
APLSApellis Pharmaceuticals, Inc.97,478$3.9M
RVMDREVOLUTION MEDICINES, INC.22,010$1.2M
ABVXAbivax SA7,500$835K
QGENQIAGEN N.V.12,500$501K
LLYELI LILLY & Co450$414K
AZNASTRAZENECA PLC2,000$394K
PFEPFIZER INC156,200$279K
GALTGALECTIN THERAPEUTICS INC19,324$54K
ACHAccendra Health Inc.22,373$51K
BMEABiomea Fusion, Inc.32,472$50K
OTLKOutlook Therapeutics, Inc.232,546$48K
PRQRProQR Therapeutics N.V.29,518$48K
IRWDIRONWOOD PHARMACEUTICALS INC13,527$47K
LCTXLineage Cell Therapeutics, Inc.29,194$46K
FLNAFilana Therapeutics Inc.27,107$46K
INOINOVIO PHARMACEUTICALS, INC.26,317$46K
OABIOmniAb Inc.29,062$46K
IVVDInvivyd, Inc.34,698$45K
PGENPRECIGEN, INC.11,608$45K
MXCTMaxCyte Inc.63,591$45K
NKTXNkarta, Inc.21,131$45K
HRTXHERON THERAPEUTICS, INC. /DE/53,399$43K
GNLXGENELUX Corp17,473$42K
TCRXTScan Therapeutics, Inc.41,740$42K
LNAILunai Bioworks Inc.102,426$42K
ALXOALX ONCOLOGY HOLDINGS INC20,623$41K
PDSBPDS Biotechnology Corp67,507$41K
PRLDPrelude Therapeutics Inc11,699$40K
OCGNOcugen, Inc.21,938$40K
CRBUCaribou Biosciences, Inc.20,612$39K
CHRSCoherus Oncology, Inc.23,018$39K
JSPRJasper Therapeutics Inc.44,165$39K
BDTXBlack Diamond Therapeutics, Inc.17,806$38K
GOSSGossamer Bio, Inc.114,766$38K
CCCCC4 Therapeutics, Inc.14,157$37K
ALTAltimmune, Inc.11,850$36K
TNYATenaya Therapeutics, Inc.51,344$36K
ATNMActinium Pharmaceuticals, Inc.35,227$35K
HUMAHumacyte Inc.54,535$33K
RANIRani Therapeutics Holdings, Inc.44,849$33K
SGMOQSANGAMO THERAPEUTICS, INC113,465$28K
ALTSALT5 Sigma Corp23,925$27K

13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.